Understand the source comparison
Comparison: GHRP-6 vs GHRP-2 vs Ipamorelin for Appetite Stimulation
GHRP-6 Acetate 20–40 min 90–120 min High (direct GHS-R1a agonist) Moderate pulse at 30–45 min Appetite stimulation, cachexia models, timed feeding protocols GHRP-2 25–45 min 60–90 min Moderate (partial agonist) Strong pulse at 30–60 min GH secretion studies, m
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- GHRP-6 Acetate
- 20–40 min
- 90–120 min
- High (direct GHS-R1a agonist)
- Moderate pulse at 30–45 min
- Appetite stimulation, cachexia models, timed feeding protocols
- GHRP-2
- 25–45 min
- 60–90 min
- Moderate (partial agonist)
- Strong pulse at 30–60 min
- GH secretion studies, minimal appetite focus
- Ipamorelin
- 30–50 min
- 45–75 min
- Low (selective GHS-R1a, no ghrelin cross-reactivity)
- Selective GH pulse, no cortisol/prolactin spike
- GH research without appetite confound
- GHRP-6 acetate is the only peptide in this class with clinically significant appetite stimulation as a primary effect. GHRP-2 produces mild hunger increases, but inconsistently. Ipamorelin was specifically designed to isolate GH release without appetite or cortisol effects, making it unsuitable for hunger research. Researchers selecting between these peptides should prioritise GHRP-6 if appetite is the dependent variable and GHRP-2 or ipamorelin if GH secretion is the focus.